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ABSTRACT
Background. The antifungal drug itraconazole inhibits angio-
genesis and Hedgehog signaling and delays tumor growth in
murine prostate cancer xenograft models. We conducted a
noncomparative, randomized, phase II study evaluating the
antitumor efficacy of two doses of oral itraconazole in men
withmetastatic prostate cancer.
Patients andMethods.We randomly assigned 46 men with
chemotherapy-naïve metastatic castration-resistant pros-
tate cancer (CRPC) to receive low-dose (200 mg/day) or
high-dose (600mg/day) itraconazole until disease progres-
sion or unacceptable toxicity. The primary endpoint was
the prostate-specific antigen (PSA) progression-free sur-
vival (PPFS) rate at 24 weeks; a 45% success rate in either
arm was prespecified as constituting clinical significance.
Secondary endpoints included the progression-free sur-
vival (PFS) rate and PSA response rate (Prostate Cancer
Working Group criteria). Exploratory outcomes included
circulating tumor cell (CTC) enumeration, serum androgen
measurements, as well as pharmacokinetic and pharmaco-
dynamic analyses.
Results. The high-dose arm enrolled to completion (n  29),
but the low-dose arm closed early (n  17) because of a pre-
specified futility rule. The PPFS rates at 24 weeks were 11.8%
in the low-dose arm and 48.0% in the high-dose arm. Theme-
dian PFS timeswere 11.9weeks and 35.9weeks, respectively.
PSA response rates were 0% and 14.3%, respectively. In addi-
tion, itraconazole had favorable effects on CTC counts, and it
suppressed Hedgehog signaling in skin biopsy samples. Itra-
conazole did not reduce serum testosterone or dehydroepi-
androstenedione sulfate levels. Common toxicities included
fatigue, nausea, anorexia, rash, and a syndrome of hypokale-
mia, hypertension, and edema.
Conclusion.High-dose itraconazole (600mg/day) hasmodest
antitumoractivity inmenwithmetastatic CRPC that is notme-
diated by testosterone suppression. The Oncologist 2013;18:
163–173
Implications for Practice: This study investigated twodoses of anoral antifungal drug, itraconazole, to determinewhether it has
antitumor activity inmenwithmetastatic castration-resistant prostate cancer. The results showed thatwhile low-dose itracona-
zole (200mg/day) didnothave significant antitumoreffects, high-dose itraconazole (600mg/day) didhave someactivity in these
patients. Moreover, the effects of itraconazole appeared to be associatedwith inhibition of Hedgehog signaling in skin biopsies, and
werenotcausedbytestosteronesuppression.Therefore, itraconazolemaybeanon-hormonal treatmentoption forpatientswithcas-
tration-resistantprostatecancerwhowish topreventordelay theuseof chemotherapy.While itraconazole isnotaseffectiveasother
novel agents for advanced prostate cancer (e.g. abiraterone, enzalutamide), it is a generic drug thatmay be considered if the cost of
theseneweragents is prohibitive, or inpartsof theworldwhereabirateroneandenzalutamidemaynotbeavailable.
INTRODUCTION
Although androgen-deprivation therapy is very effective ini-
tial therapy for men with advanced prostate cancer, all pa-
tients will eventually progress to a state known as castration-
resistant prostate cancer (CRPC), which is invariably fatal. Until
recently, life-prolonging therapies for patients with metastatic
CRPC were limited, consisting only of docetaxel chemotherapy
[1]. Inthepast2years, threeadditionalmodalitieswereaddedto
ourarmamentariumformetastaticCRPC: theautologous immu-
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notherapy product sipuleucel-T [2], the chemotherapy agent
cabazitaxel [3], and the novel androgen-biosynthesis inhibitor
abiraterone [4].Moreover, two additional agents (the bone-tar-
geting radiopharmaceutical radium-223 [5] and the androgen-
signaling inhibitor enzalutamide [6]) were recently reported to
extend survival in these patients. Despite these advances, none
of these therapies are curative, and survival times for menwith
metastatic CRPC remain short (20–24months) [7]. In this light,
novelbiological targetscontinuetobeexplored[8] inordertoex-
pand treatmentoptions formenwithCRPC.
Drugdevelopment isa lengthyandexpensiveprocess, tak-
ing, on average, 15 years and US$80 million to bring a single
drug tomarket [9]. To increase the efficiency of this process, a
drug library comprising3,000 existing compounds has been
created, enabling in vitro screening of old drugs for novel bio-
logical functions [10]. This drug library was recently screened
for agents that may inhibit angiogenesis, a potentially impor-
tant target of prostate cancer therapeutics [11]. An unex-
pected “hit” from this screen was the antifungal agent
itraconazole, which was found to inhibit endothelial cell pro-
liferation in vitro (unlike other azole antifungals) [12] and to
impede endothelial cell migration and capillary tube forma-
tion [13]. Although its antiangiogenic target is uncertain, one
study suggested that itraconazole inhibits mammalian target
of rapamycin in endothelial cells by impairing cholesterol traf-
ficking [14]. In vivo, itraconazole was found to inhibit neovas-
cularization in amouseMatrigel™ (BDBiosciences, SanDiego,
CA) model, to delay tumor growth in a castration-resistant
xenograft mousemodel (22Rv1), and to inhibit metastases in
theAT6.3prostatecancermousemodel [12]. Intriguingly, itra-
conazole was also discovered to potently inhibit Hedgehog
(Hh) signaling, a developmental pathway regulating epitheli-
al–mesenchymal interactions, cell survival, and angiogenesis
[15]. To this end, in vitro studies showed that itraconazole in-
hibited proliferation of the Hh reporter cell line Shh-Light2 by
antagonizing Smoothened [16]. Additionally, itraconazole in-
duced tumor growth inhibition in a mouse medulloblastoma
model (Ptch/ p53/) with constitutive overactivation of
Hh signaling. In this allograftmodel, itraconazole downmodu-
lated intratumoral expression ofGLI1, a Hh target gene [16].
Because itraconazole is already approvedby theU.S. Food
and Drug Administration (FDA) as an antifungal agent at oral
doses in the range of 200–600 mg/day [17], we conducted a
phase II study examining the antitumor efficacy of two doses
of itraconazole (200 mg/day and 600 mg/day) in men with
metastatic CRPC. This study was prompted by the encouraging
clinical activity of other antiangiogenic agents in CRPC patients
[18] and by other data suggesting that upregulation of Hh path-
waycomponentsmaydriveCRPC[19]. Inaddition, thecostofge-
neric itraconazole is only a fraction of that of other novel
therapies forCRPC, suchasabirateroneandenzalutamide.
PATIENTS ANDMETHODS
Patients
Our target population was men with metastatic CRPC who had
not receivedcytotoxic chemotherapy. Patientswere required to
have histologically confirmed prostate adenocarcinoma, pro-
gressive disease despite “castration levels” of serum testoster-
one (50ng/dL), andradiographically visibledistantmetastases
oncomputedtomography(CT)ortechnetium-99bonescans.Pa-
tients had to have three or more rising serum prostate-specific
antigen(PSA)valuestaken4weeksapartwiththelastvaluebeing
2.0ng/mL, inaccordancewithProstateCancerWorkingGroup
(PCWG) guidelines [20]. Other eligibility criteria included age
18years, anEasternCooperativeOncologyGroup (ECOG)per-
formancestatus score2,a lifeexpectancy6months, andad-
equatekidney, liver, andbonemarrowfunction.
Patients were excluded if they had received an oral antian-
drogen within 6 weeks, had ever received chemotherapy for
metastatic CRPC, took systemic corticosteroids, had a malab-
sorptionsyndrome,tookdrugsmetabolizedbycytochromeP450
(CYP)3A4,hadapriormalignancywithin3years,hadmajor infec-
tious, pulmonary, or cardiac illnesses, had symptomatic conges-
tive heart failure, or had a corrected QT interval450msec on
electrocardiography.Priorketoconazoletreatmentwaspermitted.
The review boards at all institutions approved the study,
which was conducted according to good clinical practice
guidelines. All patients providedwritten informed-consent.
Study Design
This was a noncomparative, open-label, randomized, phase II
study conducted at four institutions of the Prostate Cancer
Clinical Trials Consortium [21]. Patients were randomized
(1:1) to receive low-dose (200mg/day) or high-dose (600mg/
day) itraconazole.Thesedoseswerechosenbecause itracona-
zole is alreadyFDAapprovedasanantifungal agent atdoses in
the range of 200–600mg/day and because data from animal
models suggestedthat,although200mgmightbesufficient to
inhibit angiogenesis, doses 600 mg might be required to
suppress Hh signaling.
Itraconazole was supplied as generic 100-mg capsules
(Sandoz,Princeton,NJ).Patientsassignedtothe low-dosearm
received two100-mgcapsulesoncedaily; patients in thehigh-
dosearmreceivedthree100-mgcapsules twicedaily.Because
itraconazole absorption depends on gastric acidity, patients
were instructed to take itraconazole capsules with a carbon-
atedbeverageand togetherwith foodorwithin30minutesaf-
ter a meal. Patients were not permitted to take concurrent
antacids, histamine blockers, or proton pump inhibitors. Treat-
ment continuedeitheruntil unmanageabledrug-related toxicity
or until clinical or radiographic progression. Importantly, treat-
mentwasnotdiscontinued forPSAelevations [20].
Assessments
Clinical evaluations included a physical examination, vital sign
measurements, assessment of ECOG score, review of con-
comitant medications, laboratory evaluations (chemical and
hematologic studies), and review of adverse events andwere
performed every 4 weeks. Efficacy assessments included se-
rum PSA measurement every 4 weeks and CT (chest, abdo-
men, and pelvis) and whole-body technetium-99 bone scan
evaluations every 12weeks.
OutcomeMeasures
The primary endpoint was freedom from PSA progression (the
PSA progression-free survival [PPFS] rate) at 24weeks after ran-
domization. PSA progressionwas defined as a25% increase in
PSA from nadir (and by 2 ng/mL), requiring confirmation 4
weeks later (PCWGcriteria) [20]. Although the PPFS rate is not a
validated surrogate of clinical benefit, this endpoint was chosen
in order to screen for preliminary evidence of clinical activity in
the setting of a small phase II trial. A key secondary endpoint,
164 Itraconazole for Prostate Cancer
©AlphaMed Press 2013
whichmightbe consideredmore clinicallymeaningful,was free-
dom from progression (the progression-free survival [PFS] rate)
at 24weeks. Progressionwasdefined [20] as clinical progression
(worsening disease-related symptoms or new cancer-related
complications), radiographic progression (onCT scan,20%en-
largement in the sum diameter of soft-tissue target lesions ac-
cording to the Response Evaluation in Solid Tumors [RECIST],
version1.0 [22];onbonescan, twoormorenewconfirmedbone
lesions), ordeath,whicheveroccurred first.
Secondary endpoints included themedian PPFS duration,
PSA response rate (50% PSA decline from baseline, main-
tained for 4 weeks), best PSA response (maximal percent-
age PSA decrease from baseline), median PFS time, and
objective response rate inmeasurable soft-tissue lesions (par-
tial response,30%decrease in thesumdiameterof target le-
sions; progressive disease, 20% increase in the sum
diameter of target lesions or one or more new lesion; stable
disease, change in the sum diameter of target lesions that do
notmeet theaboveparameters;RECIST, version1.0 [22]).A fi-
nal secondary endpoint was safety; adverse events were
graded using the National Cancer Institute Common Toxicity
Criteria for Adverse Events, version 3.0.
Circulating Tumor Cell Analysis
Blood samples (7.5 mL) for circulating tumor cell (CTC) enu-
merationwere collected at baseline and after 4weeks and 12
weeks on study andwere analyzed using the CellSearch sys-
tem (Veridex, Raritan, NJ), as previously described [23]. Re-
sults were expressed as numbers of CTCs per 7.5mL blood.
Pharmacokinetics and Pharmacodynamics
Pharmacokinetics
Plasma samples were collected at baseline and prior to itra-
conazole administration (minimum concentration [Cmin]) and
at 4 weeks and 12 weeks on study. Itraconazole and 4-hy-
droxyitraconazole concentrations were assessed using a vali-
dated liquid chromatography–mass spectrometry assay, over
the range of 2–2,000 ng/mL.
Analysis of Adrenal Axis
To examine whether or not itraconazole suppressed adrenal
cortical function, several adrenal-axis hormones were evalu-
atedat baseline andafter 4weeks and12weekson study: tes-
tosterone, dehydroepiandrostenedione sulfate (DHEA-S),
cortisol, aldosterone, and adrenocorticotropic hormone
(ACTH). Serum testosterone and serum aldosterone were
measuredusing a liquid chromatography–mass spectrometry
assay. Using this method, the lower limit of detection of tes-
tosterone is 1 ng/dL. Serum DHEA-S and plasma ACTH levels
were measured using a chemiluminescence immunoassay.
Serumcortisolwasmeasuredusing anenzyme immunoassay.
Vascular Endothelial Growth Factor Levels
To evaluate antiangiogenic effects in an exploratory analysis,
plasma was collected for vascular endothelial growth factor
(VEGF) measurement at baseline and after 4 weeks and 12
weeks on study. Total VEGF concentrations were measured
using the Quantikine enzyme-linked immunosorbent assay
(R&D Systems,Minneapolis,MN).
Assessed for eligibility (n = 51) 
Excluded (n = 5) 
♦  Did not meet eligibility criteria (n = 4) 
♦  Declined to participate (n = 1) 
Analyzed (n = 17) 
♦  Evaluable for the primary endpoint (n = 17)  
♦  Evaluable for safety (n = 17) 
Stopped treatment due to progression (n = 15) 
Stopped treatment due to toxicity (n = 1) 
Withdrew consent for other reasons (n = 1)
Allocated to low-dose itraconazole (n = 17*) 
♦  Received allocated treatment (n = 17) 
♦  Did not receive allocated treatment (n = 0) 
        *This arm closed early for futility 
Stopped treatment due to progression (n = 22) 
Stopped treatment due to toxicity (n = 4) 
Withdrew consent for other reasons (n = 3)
Allocated to high-dose itraconazole (n = 29) 
♦  Received allocated treatment (n = 29) 
♦  Did not receive allocated treatment (n = 0) 
Analyzed (n = 29) 
♦  Evaluable for the primary endpoint (n = 25)  
♦  Evaluable for safety (n = 29) 
Allocation
Analysis 
Follow-Up 
Randomized (n = 46) 
Enrollment
Figure 1. Consort diagram.
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Hh Pathway Analysis
BecauseHhsignaling ispresent in skinandhair follicles,weex-
amined GLI1 mRNA expression (a marker of Hh pathway acti-
vation) using 3-mm skin punch biopsies from hair-containing
skin obtained at baseline and after 4 weeks and 12 weeks on
study. RNA was extracted from skin biopsy specimens, and
GLI1 expression levels were assessed by real-time reverse-
transcription polymerase chain reaction (SABiosciences-Qia-
gen, Frederick,MD), as previously described [24].
Statistical Analysis
Basedonprior studies [25],weestimatedthatupto20%ofpa-
tients with metastatic CRPC who had not received prior che-
motherapy would be free from PSA progression (as defined
above) after 24 weeks on study. We hypothesized that itra-
conazole (at either dose level)wouldprevent PSAprogression
at 24 weeks in45% ofmen (i.e., we considered a 25% abso-
lute improvement20% tobe clinicallymeaningful). Twenty-
nine patients per arm would grant 83% power to detect an
improvement in the 24-week PPFS rate (the primary end-
point) from20% (historical controls) to 45%using a two-sided
 of 0.05. A 45% 24-week PPFS rate in each arm was pre-
defined to constitute a success (indicating worthiness for fur-
ther study). To monitor for treatment futility, both arms had
prespecified early-stopping rules thatwere applied after nine
(one third of the total) and 15 (one half of the total) patients
were evaluable for the primary endpoint. In each arm, if there
were fewer than two of nine men who achieved the primary
endpoint or if there were fewer than four of 15 men who
achieved the primary endpoint, then that armwould close for
futility. These stopping rules were consistent with observing
an upper bound of a one-sided exact 90% confidence interval
(CI) that excluded our hypothesized success rate of 45%.
The study was not powered to allow inferential statistics
comparing treatment arms. Kaplan–Meier analysis was used
to estimate time-to-event endpoints and 95% CIs. Patient
baseline characteristics were compared between arms using
Fisher’s exact test, Student’s t-test, or theWilcoxon rank-sum
test (p-valuesaremerelydescriptivebecausealldifferencesarea
resultofchancevariationinducedbyrandomization).Pharmaco-
dynamic and pharmacokinetic endpoints were reported as
trends over time using descriptive statistics; associations be-
tween these exploratory measures and clinical outcomes were
soughtusingPearson’s correlation coefficient (r).
RESULTS
Patients
The high-dose arm was enrolled to completion (29 patients)
whereas the low-dose arm closed early because of futility af-
ter 17 men were enrolled (in this arm, there were two suc-
cesses in the firstninepatientsandenrollmentcontinueduntil
15were evaluable for the primary endpoint; at that time, two
additional patients were enrolled but no more achieved the
Table 1. Baseline demographic and clinical characteristics
Baseline characteristic
Low-dose: 200mg/day
(n 17)
High-dose: 600mg/day
(n 29)
p-valuen % n %
Median (range) age, yrs 73 (60–81) 71 (52–89) .30
Race
White 10/17 58.8 21/29 72.4 .52
Nonwhite 7/17 41.2 8/29 27.6
Mean (range) Gleason score 7.4 (5–9) 7.6 (5–10) .51
Median (range) baseline PSA, ng/mL 29.2 (7.0–1,989.5) 43.5 (2.6–234.5) .18
Median (range) baseline PSA doubling time,mos 2.7 (1.4–6.8) 2.4 (0.9–10.7) .75
ECOGperformance status score
0 11/17 64.7 18/29 62.1 .99
1 or 2 6/17 35.3 11/29 37.9
Metastatic sites
Bone only 3/17 17.7 12/29 41.4 .37
Visceral/soft tissue only 5/17 29.4 6/29 20.7
Bone and visceral/soft tissue 9/17 52.9 11/29 37.9
Mean (range) number ofmetastases 6.5 (1–27) 5.5 (1–14) .51
Mean (range) number prior hormonal therapies 2.6 (1–5) 2.5 (1–5) .85
Prior ketoconazole
Yes 5/17 29.4 9/29 31.0 .99
No 12/17 70.6 20/29 69.0
Median (range) baseline testosterone, ng/dL 5 (1–20) 6 (1–26) .41
Median (range) baseline hemoglobin, g/dL 12.5 (9.0–14.7) 13.0 (9.9–15.0) .29
Median (range) baseline albumin, g/dL 4.0 (3.5–5.0) 4.1 (3.4–4.7) .83
Median (range) baseline alkaline phosphatase, U/L 99 (55–454) 89 (47–733) .64
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PSA, prostate specific antigen.
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primary endpoint) (Fig. 1). Baseline patient characteristics ap-
pearedgenerallybalanced (Table1); therewasa trend toward
lower baseline PSA levels in the low-dose arm and a trend to-
ward more bone-only metastases in the high-dose arm. One
thirdofpatients inbotharmshadreceivedpriorketoconazole.
Themedian treatment durations were 11.9 weeks in the low-
dose arm and 23.6weeks in the high-dose arm.
Primary Endpoint
All 17patients in the low-dosearmand25of 29patients in the
high-dose arm (four men came off study before 24 weeks be-
cause of toxicity) were evaluable for the primary endpoint. In
the low-dose arm, the 24-week PPFS rate estimatewas 11.8%
(two of 17 men; 95% CI, 1.5%–36.4%), failing to achieve the
primary endpoint. Conversely, the high-dose armmet the pri-
mary endpoint, demonstrating a 24-week PPFS rate estimate
of 48.0% (12 of 25men; 95%CI, 27.8%–68.7%).
Secondary Endpoints
The median PPFS times were 11.9 weeks (95% CI, 5.6–20.0
weeks) and 17.0 weeks (95% CI, 12.4–32.0 weeks) in the low-
dose and high-dose arms, respectively (Fig. 2A). The 24-week
PFS rate estimates were 18.8% (95% CI, 6.8%–52.0%) and
61.6% (95% CI, 46.1%–84.6%) in the two arms, respectively.
The median PFS times were 11.9 weeks (95% CI, 11.9–28.1
weeks) and 35.9 weeks (95% CI, 21.6–47.4 weeks) (Fig. 2B).
PSA response rates (50%PSAdecline)were0% (95%CI, 0%–
19.5%) and 14.3% (95% CI, 4.0%–32.7%) (Fig. 2C), respec-
tively. Among those with measurable disease at baseline,
7.7% (95% CI, 1.8%–33.9%) and 11.1% (95% CI, 3.4%–33.1%)
of patients in the two arms achieved a partial objective re-
sponse, respectively (Fig. 2D). Finally, the median PSA dou-
bling time (PSADT) estimates were longer in both study arms
after treatment initiation, although this change was only sta-
tistically significant in the high-dose arm (baseline median
PSADT, 2.4months; on-studymedian PSADT, 7.7months; dif-
ference, 5.3 months; p  .01) and not in the low-dose arm
(baseline median PSADT, 2.7 months; on-study median
PSADT, 5.8months; difference,3.1months; p .07).
Safety
Adverse events were generally more frequent in the high-
dose than in the low-dose arm (Table 2). Common toxicities in
both arms included fatigue, pain, nausea and constipation.
Also, a constellation of adverse events comprising hyperten-
sion, hypokalemia, and edema was of special interest, sug-
gesting a syndrome of secondary mineralocorticoid excess
(see adrenal-axis evaluations below). Manifestations of this
syndromeweremore frequent in the high-dose arm.
Grade 3 adverse events in the low-dose arm included fa-
tigue (5.9%), anorexia (5.9%), and rash (5.9%). Grade 3 toxici-
Figure 2. Clinical effects of itraconazole. (A): Kaplan–Meier curves of PPFS inmen receiving low-dose and high-dose itraconazole. (B):
Kaplan–Meier curves of PFS in each treatment arm. (C):Waterfall plots showingbest PSA responses amongmen receiving low-dose and
high-dose itraconazole. Theasteriskdenotesa clippedPSAvalue. Prior treatmentwithketoconazole is indicatedby thehashedbars. (D):
Waterfall plots showing best objective responses inmeasurable lesions according to Response Evaluation Criteria in Solid Tumors, ver-
sion 1.0. Prior treatmentwith ketoconazole is indicated by the hashed bars (and daggers).
Abbreviations: CI, confidence interval; PFS, progression-free survival; PPFS, PSAprogression-free survival; PSA,prostate-specific antigen.
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ties in the high-dose arm included hypokalemia (10.3%),
hypertension (6.9%), and rash (3.4%). There were no grade 4
toxicities. Thepercentagesofpatientswhocameoff studyasa
result of toxicitieswere5.9% in the low-dosearm (onepatient
developedarash)and13.8%inthehigh-dosearm(onepatient
developed fatigue, one patient developed anorexia, one pa-
tient developed a rash, and one patient developed temporal
arteritis [not drug related]).
CTC Enumeration
Fifteenpatients in the low-dosearm(88.2%)and25patients in
thehigh-dosearm(86.2%)hadpairedbaselineandpost-treat-
ment blood samples collected for CTC enumeration. Thirty-
twomen had favorable baseline CTC counts (5 CTCs per 7.5
mL blood); 96.9% of them retained favorable CTC counts for
12 weeks. Eight men had unfavorable baseline CTC counts (5
CTCsper 7.5mLblood); five (62.5%) of themconverted to favor-
able CTC counts post-treatment. Data from those patients con-
verting from unfavorable to favorable CTC counts are shown
here:2833,1531,730,630,and630CTCsper7.5mLblood.
Pharmacokinetics and Pharmacodynamics
Pharmacokinetics
Sixteen patients in the low-dose arm (94.1%) and 26 patients
in the high-dose arm (89.7%) had paired baseline and post-
treatment plasma samples for pharmacokinetic analyses. The
mean plasma itraconazole trough concentration (Cmin) values
were 370.0 ng/mL (range, 86.9–653.1 ng/mL) and 1,517.0
ng/mL (range, 673.8–2,360.2 ng/mL) in low- and high-dose
arms, respectively. The mean plasma 4-hydroxyitraconazole
Cmin values were 723.5 ng/mL (range, 289.2–1,157.8 ng/mL)
and 2,630.8 ng/mL (range, 1,036.0–4,225.6 ng/mL), respec-
tively. Therewere significant correlationsbetweenahigher itra-
conazoleCmin levelandbothalongerPPFSduration(r0.56;p
.003)andagreaterPSAdecline (r0.39;p .03) (supplemental
onlineFig.1).Similarstatisticallysignificantcorrelationswereob-
servedwith4-hydroxyitraconazole (datanot shown).
Adrenal Axis Analysis
Neither low-dose nor high-dose itraconazole caused suppres-
sion of serum testosterone or DHEA-S levels. Unexpectedly,
low-dose and high-dose itraconazole appeared to slightly in-
crease serum testosterone (Fig. 3A) and DHEA-S (Fig. 3B) lev-
els, respectively. Additionally, high-dose (but not low-dose)
itraconazole potently suppressed serumaldosterone (Fig. 3C)
while raising plasma ACTH (Fig. 3D). There were no effects
with either itraconazole dose on serum cortisol at 4 weeks or
12weeks (data not shown).
VEGFAnalysis
Low-dose itraconazole was not associated with a change in
plasmaVEGF level at either4weeks (p .59)or 12weeks (p
.11). Likewise, high-dose itraconazolewasnotassociatedwith
a VEGF level change at either 4 weeks (p  .72) or 12 weeks
(p .76).
Hh pathway analysis
Fifteenpatients in the low-dosearm(88.2%)and25patients in
thehigh-dosearm(86.2%)hadpairedbaselineandpost-treat-
ment skin punchbiopsy samples collected forGLI1expression
analysis.GLI1wasdownmodulated in33%and68%ofpatients
in the low-andhigh-dosearms, respectively (Fig. 4A). Theper-
Table 2. Adverse events
Adverse event
Low-dose: 200mg/day (n 17) High-dose: 600mg/day (n 29)
All grades % Grade 3 % All grades % Grade 3 %
Fatigue 9 52.9 1 5.9 15 51.7
Pain 7 41.2 13 44.8
Nausea 4 23.5 11 37.9
Constipation 2 11.8 10 34.5
Edema (peripheral) 4 23.5 10 34.5
Hypertension 0 0.0 9 31.0 2 6.9
Diarrhea 1 5.9 8 27.6
Anorexia 2 11.8 1 5.9 7 24.1
Headache 2 11.8 6 20.7
Rash 3 17.6 1 5.9 5 17.2 1 3.4
Vomiting 2 11.8 5 17.2
Dyspnea 1 5.9 5 17.2
Hypokalemia 0 0.0 5 17.2 3 10.3
Urinary frequency 4 23.5 4 13.8
Hot flashes 3 17.6 4 13.8
Cough 3 17.6 3 10.3
Peripheral neuropathy 3 17.6 3 10.3
Dizziness 0 0.0 3 10.3
Drymouth 0 0.0 3 10.3
Infection (respiratory) 0 0.0 3 10.3
Taste alteration 0 0.0 3 10.3
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Figure 3. Endocrine effects of itraconazole. (A): Effect of low- and high-dose itraconazole on serum testosterone concentrations (data
are shown as medians and interquartile ranges). (B): Effect of low- and high-dose itraconazole on serum DHEA-S concentrations. (C):
Effectof low-andhigh-dose itraconazoleonserumaldosteroneconcentrations. (D):Effectof low-andhigh-dose itraconazoleonplasma
ACTH concentrations.
Abbreviations: ACTH, adrenocorticotropic hormone; DHEA-S, dehydroepiandrostenedione-sulfate.
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centage of patients who achieved a twofold or greater down-
modulation in GLI1 with itraconazole was 28% (11 of 40),
compared with 68% of patients receiving vismodegib (a po-
tent Hh pathway antagonist) in prior studies [26]. Themedian
PPFS time was longer in men who achievedGLI1 downmodu-
lation (p .028) (Fig. 4B) and there was also a trend toward a
longer PFS interval in men with GLI1 downmodulation (p 
.128) (Fig. 4C). Finally, there was a significant correlation be-
tweena strongerGLI1downmodulation anda greater PSAde-
cline (r0.38;p .01) (Fig. 4D). Interestingly, all fivepatients
who achieved favorable CTC conversions also had down-
modulation ofGLI1.
DISCUSSION
Thisphase II study is the first toexamine itraconazoleasanan-
tineoplastic agent in human cancer. We demonstrate that, in
men with metastatic chemotherapy-untreated CRPC, low-
dose itraconazole (200mg/day) lacks significant antitumoref-
ficacy, whereas high-dose itraconazole (600 mg/day) may
havemodest clinical activity, as suggested by longer PPFS and
PFS times than in historical data [25]. Importantly, the PFS du-
ration observed here (35.9 weeks) is comparable with PFS
time estimates (range, 30–40weeks) of other FDA-approved
and experimental agents in this patient population (mitoxan-
trone, docetaxel, tasquinimod, and cabozantinib) [1, 18, 27],
although thePFS time is not a surrogateof clinical benefit. No-
tably, itraconazole’s activity does not appear to be mediated
by testosteronesuppression (althoughacomprehensiveanal-
ysis of the androgen axis was not conducted), and it may pos-
sibly be associated with downmodulation of Hh signaling.
Alternatively, itraconazole may have beneficial off-target ef-
fects on other unknown targets.
Figure4. GLI1modulationby itraconazole. (A):Waterfall plots showingGLI1modulation in skinpunchbiopsies, depictedas fold change
inGLIexpressionpost-treatment comparedwithbaselinevalues. (B):Kaplan–Meier curvesdepictingPPFSaccording toGLI1modulation
status. (C): Kaplan–Meier curves depicting PFS according to GLI1modulation status. (D): Scatterplot showing the association between
GLI1modulation and PSA change.
Abbreviations: PFS, progression-free survival; PPFS, PSA progression-free survival; PSA, prostate-specific antigen.
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Another azole antifungal, ketoconazole, has beenusedoff
label formanyyearsasa therapy forCRPC.Ketoconazole func-
tions by suppressing extragonadal androgen synthesis [28]
(nonselectively inhibiting multiple CYP enzymes), but carries
significant toxicity without evidence that it extends the sur-
vival duration [29]. However, the selective CYP17 inhibitor
abiraterone was shown to improve survival outcomes inmen
with docetaxel-pretreated metastatic CRPC, [4], resulting in
its FDA approval. Here, we demonstrate that itraconazole
does not suppress circulating testosterone or DHEA-S levels
(although androstenedione and dihydrotestosterone levels
were not measured), suggesting an alternative or additional
antitumor mechanism. Moreover, itraconazole appeared to
have activity in both ketoconazole-pretreated and ketocona-
zole-naïve patients.
Tumor angiogenesis and Hh signaling are both involved in
prostate cancer growth, progression, andmetastasis [15, 30].
Although blocking each pathway separately has failed to yield
Figure 4. Continued.
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new prostate cancer therapeutics [26, 31], inhibition of both
pathways simultaneously with itraconazole represents a ra-
tional approach. In this study, we did not observemodulation
of circulating VEGF levels, but that does not necessarily mean
that itraconazole lacksantiangiogeniceffects inman.Ourabil-
ity to interrogate angiogenesis was limited by the lack of tu-
mor biopsy samples and because we evaluated only one of
many circulating angiogenic factors (although none have con-
sistently been associatedwith clinical benefit from antiangio-
genic therapies). Additionally, although we observed GLI1
downmodulation in skin biopsy samples, we did not interro-
gateHhsignaling in tumors themselves; therefore,weprovide
only indirect evidence that Hh pathway suppression is a po-
tential mechanism of action of itraconazole. Finally, the asso-
ciation between GLI1 downmodulation and itraconazole’s
clinical activity may not be causal, and it may simply reflect a
pharmacodynamic effect that is not linked to drug efficacy.
Nevertheless, the results of this study provide the impetus to
examine other more potent Hh pathway inhibitors (e.g., vis-
modegib, LDE225) inmenwith CRPC.
Ofparticular interestwas theoccurrenceof a syndromeof
hypokalemia, hypertension, and edema in a dose-dependent
manner. Although thesemanifestations are usually related to
hyperaldosteronism [32], aldosterone levels were potently
suppressed in our patients. This raises the possibility of a syn-
drome of secondary mineralocorticoid excess (with elevated
aldosteroneprecursors), ashasbeen reported inabiraterone-
treated patients [4, 33]. To this end,we discovered raised lev-
els of corticosterone and deoxycorticosterone in a patient
who developed all three features of this syndrome. However,
unlike abiraterone (and ketoconazole), itraconazole did not
suppress cortisol production and does not require glucocorti-
coid supplementation. Indeed, the combination of itracona-
zole and corticosteroids is contraindicated and can induce
Cushing’s syndrome by impairing corticosteroid metabolism
by CYP3A4 [34]. Finally, the slight rises observed in serum tes-
tosterone and DHEA-S levels may have resulted from eleva-
tion of upstreamACTH, although these increases in androgen
levels weremodest.
Inconclusion, thisstudysuggeststhathigh-dose itraconazole
(600mg/day) may havemodest antitumor activity in men with
metastatic CRPC that could potentially be associated with Hh
pathway suppression, although an androgen-mediated effect
cannotbeexcluded.Ongoing trials arenowassessing the impact
of itraconazole as an antineoplastic agent in patients with lung
cancer,breast cancer, andbasal cell carcinoma.Futurestudies in
prostate cancerpatientswill compare itraconazolewithplacebo
inmenwithnonmetastatic CRPC, aiming toextend themetasta-
sis-free survival duration in this population. In addition, clinical
trials using more potent Hh antagonists (e.g., vismodegib,
LDE225) inmenwithCRPCarealsobeingplanned.
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